Impact of genetic polymorphisms in the clinical response of oral inhibitors of the platelet P2Y12 adenosine diphosphate (ADP) receptor

被引：0
|
作者：
Simon, T. [1 ]
机构：
[1] Univ Paris 06, AP HP, Serv Pharmacol, F-75252 Paris 05, France
来源：
ANNALES DE CARDIOLOGIE ET D ANGEIOLOGIE | 2010年 / 59卷
关键词：
Pharmacogenetics; Antiplatelet; Thienopyridine; Prognosis; Cardiovascular disease; PERCUTANEOUS CORONARY INTERVENTION; OF-FUNCTION POLYMORPHISM; STENT THROMBOSIS; ANTIAGGREGATING ACTIVITY; CYP2C19; GENOTYPE; CLOPIDOGREL; OUTCOMES; PRASUGREL; THERAPY; TRIAL;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Dual antiplatelet therapy with clopidogrel combined to aspirin reduces ischemic events in a wide range of patients with cardiovascular disease. However, a large interindividual variability has been observed in the pharmacodynamics response of clopidogrel with lower platelet inhibition associated with increased risk for major adverse cardiovascular events. Multiple mechanisms have been proposed for the variable response to clopidogrel, among which the impact of pharmacogenetic seems to play an important role. This article reviews the role of genetic polymorphisms in the clinical impact of oral inhibitors of the platelet P2Y12 adenosine diphosphate (ADP) receptor. (C) 2010 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：S90 / S94
页数：5
相关论文
共 50 条
  • [21] Pharmacology of the platelet P2Y12 receptor
    von Kuegelgen, Ivar
    PURINERGIC SIGNALLING, 2018, 14 : S8 - S9
  • [22] The structural landscape of the ADP receptor P2Y12
    Schoeneberg, T.
    PURINERGIC SIGNALLING, 2012, 8 (01) : 118 - 118
  • [23] Loading with Oral P2Y12 Receptor Inhibitors: To Crush or Not to Crush?
    Alexopoulos, Dimitrios
    Dragasis, Stylianos
    Kafkas, Nikolaos
    THROMBOSIS AND HAEMOSTASIS, 2019, 119 (07) : 1037 - 1047
  • [24] Regulation of protein kinase C by the platelet P2Y12 ADP receptor.
    Lova, P
    Guidetti, GF
    Campus, F
    Bernardi, B
    Balduini, C
    Torti, M
    BLOOD, 2005, 106 (11) : 471A - 471A
  • [25] Antiplatelet Therapy Prasugrel: A Novel Platelet ADP P2Y12 Receptor Antagonist
    Mousa, Shaker A.
    Jeske, Walter P.
    Fareed, Jawed
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2010, 16 (02) : 170 - 176
  • [26] Genetic variants of platelet ADP receptor P2Y12 associated with changed platelet functional activity and development of cardiovascular diseases
    O. V. Sirotkina
    A. M. Zabotina
    O. A. Berkovich
    E. A. Bazhenova
    T. V. Vavilova
    A. L. Schwarzman
    Russian Journal of Genetics, 2009, 45 : 218 - 223
  • [27] Genetic variants of platelet ADP receptor P2Y12 associated with changed platelet functional activity and development of cardiovascular diseases
    Sirotkina, O. V.
    Zabotina, A. M.
    Berkovich, O. A.
    Bazhenova, E. A.
    Vavilova, T. V.
    Schwarzman, A. L.
    RUSSIAN JOURNAL OF GENETICS, 2009, 45 (02) : 218 - 223
  • [28] Characteristics of new P2Y12 inhibitors: selection of P2Y12 inhibitors in clinical practice
    Golino, Paolo
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2013, 14 : S22 - S30
  • [29] Genetic polymorphisms of the platelet receptors P2Y12, P2Y1, and Gl Ilia and response to aspirin and clopidogrel
    Lev, Eli I.
    Patel, Rajnikant T.
    Guthikonda, Sasidhar
    Lopez, David
    Bray, Paul F.
    Kleiman, Neal S.
    THROMBOSIS RESEARCH, 2007, 119 (03) : 355 - 360
  • [30] Usefulness of the INNOVANCE® PFA P2Y test cartridge for the detection of patients with congenital defects of the platelet P2Y12 receptor for adenosine diphosphate
    Scavone, Mariangela
    Germanovich, Ksenia
    Femia, Eti A.
    Cattaneo, Marco
    THROMBOSIS RESEARCH, 2014, 133 (02) : 254 - 256
12345